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Abstract
Sildenafil citrate revolutionized the practice of sexual medicine upon its federal regulatory agency approval approximately
15 years ago as the prototypical phosphodiesterase type 5 inhibitor indicated for the treatment of male erectile dysfunction.
We now provide scientific support for its alternative use in the management of priapism, a clinical disorder of prolonged
and uncontrolled penile erection. Sildenafil administered continuously to sickle cell mice, which show a priapism
phenotype, reverses oxidative/nitrosative stress effects in the penis, mainly via reversion of uncoupled endothelial nitric
oxide synthase to the functional coupled state of the enzyme, which in turn corrects aberrant signaling and function of the
nitric oxide/cyclic GMP/protein kinase G/phosphodiesterase type 5 cascade. Priapism tendencies in these mice are reverted
partially toward normal neurostimulated erection frequencies and durations after sildenafil treatment in association with
normalized cyclic GMP concentration, protein kinase G activity and phosphodiesterase type 5 activity in the penis. Thus,
sildenafil exerts pleiotropic effects in the penis that extend to diverse erection disorders.
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Introduction
Recurrent ischemic priapism, a disorder of non-willful, excessive
penile erection, occurs commonly in the sickle cell disease (SCD)
patient population and is associated with significant adverse
consequences including erectile tissue damage, erectile dysfunc-
tion, and psychological distress [1]. The molecular pathophysiol-
ogy of this erection disorder has only recently been scientifically
investigated. Current advances in this field suggest the prominent
role of aberrant function of the nitric oxide (NO)-based signal
transduction pathway, which is well-described as the main
mediatory system for penile erection [2]. Exaggerated erectile
responses consistent with priapism are observed in mice lacking
the gene for endothelial NO synthase (eNOS), which catalyzes
endothelial NO production [3], [4]. Defective phosphodiesterase
type 5 (PDE5) regulatory function in the penis accounts for these
responses, resulting from altered endothelial NO signaling with
detrimental effects on downstream pathway effector molecules,
cGMP and cGMP-regulatory protein kinase G (PKG), which
regulate PDE5 expression and activity [4], [5]. PDE5 dysregula-
tion also occurs in the penis of a transgenic mouse model of severe
sickle cell disease (sickle cell mice) [4], which show a priapism
phenotype [6–8]. Penile overproduction of adenosine [9], [10] and
upregulation of opiorphins (enzymes involved in the polyamine
synthesis) [11] in sickle cell mouse penes also may contribute to the
priapism phenotype observed in this experimental animal model.
Given the emerging central role of altered NO signaling in the
pathophysiology of priapism associated with SCD, we hypothe-
sized that restored normal NO/cGMP/PKG/PDE5-mediated
penile vascular homeostasis in the penis via sustained pharmaco-
therapeutic inhibitory targeting of PDE5 would attenuate this
disorder. In uncontrolled clinical studies involving men with SCD,
PDE5 inhibitor therapy administered by continuous, long-term
dosing unassociated with sexual stimulation proved efficacious in
reducing priapism-related events [12], [13]. However, the precise
pathogenic mechanisms resulting in altered NO signaling in the
penis leading to SCD-associated priapism are unknown. More-
over, the mechanism of action of regimented PDE5 inhibitor
therapy as an intervention for priapism has not been fully defined.
Therefore, this study was designed, using the sickle cell mouse
model, to: 1) investigate the pathogenic mechanisms in the penis
causing endothelial NO/cGMP/PKG/PDE5 derangements that
predispose priapism, and 2) identify a pharmacologic mechanism
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by which PDE5 inhibitors potentially serve as a therapy for
priapism related to SCD.
Materials and Methods
Mouse Model of Human Sickle Cell Disease
Transgenic sickle cell (Sickle) mice with knockout of all mouse
hemoglobin genes and expressing exclusively human sickle
hemoglobin were developed at Lawrence Berkeley National
Laboratory [14]. A breeding colony at the National Institutes of
Health (NIH) generated animals for this study by mating sickle
male mice to hemizygous females (approximately 15 generations).
Because C57BL/6 is one of the background strains for the
transgenic sickle mice, C57BL/6 was chosen as WT control.
Additional control animals were hemizygous (Hemi) littermates.
All were males ages 4 to 6 months old. Mice were pathogen free
and received routine NIH rodent chow and water. Studies were
approved by the animal care and use committees of the Johns
Hopkins Hospital.
PDE5 Inhibitor Therapy
WT and Hemi mice received oral treatment with the PDE5
inhibitor, sildenafil citrate (Viagra, Pfizer) for 3 weeks, which was
provided by mixing drug (100 mg/kg/day) into semi-soft rodent
chow (Bioserv; 426 g/d) [15], [16]. Mean free plasma concen-
tration of sildenafil was approximately 10–20 nM, a concentration
of drug that inhibits 50% of PDE5 activity. This is comparable to
levels obtained in humans at doses of 25 mg dosed three times a
day and reflects the near 100-fold higher rate of metabolism of
sildenafil in the mouse [16].
Physiologic Erection Studies
In vivo erectile function in response to cavernous nerve
stimulation (CNS) was studied in anesthetized mice as previously
described [6]. Briefly, surgical pelvic dissection was performed for
CNS and intracavernous pressure (ICP) monitoring. Each mouse
underwent CNS at a frequency of 15 Hz and pulse width of 30
milliseconds. The application of 2 volts was used in the current
protocol to achieve a significant and consistent erectile response.
The primary in vivo erectile function end point to determine the
influence of PDE5 inhibitor therapy on prolonged erections
observed in Sickle mice was the frequency of spontaneous
erections per hour calculated pre and post CNS [6]. Increases in
ICP pressure were also measured after direct intracavernous
injection of sildenafil citrate (30 nmol/kg) and the NO donor
DEA/NO (0.3 mg/kg) [4].
Collection of Tissue Specimens
Penile specimens were obtained by cutting the crura of the
corpus cavernosum at the point of adhesion to the lower pubic
bone. Samples were snap frozen in liquid nitrogen, and stored at
280uC until processing for molecular analyses. Molecular analyses
were determined under basal (unstimulated) and stimulated
conditions. For stimulated conditions, penes were removed during
maximal ICP pressures during CNS [4].
Cyclic Nucleotide Assay
Quantitative assays for cGMP were performed using a
commercial enzyme immunoassay kit (Amersham, Piscataway,
NJ). For penile cGMP content, frozen penile tissue was
homogenized in 6% trichloroacetic acid (1 ml/100 mg tissue),
centrifuged, and extracted with water-saturated diethyl ether [4].
cGMP was expressed as fmol/mg protein.
NOS, PDE5, and PKG Activity Assays
Penile NOS activity was assayed by radiolabelled L-arginine to
L-citrulline conversion [4]. Measurements were performed in the
presence [for constitutive NOS activity] or absence [for inducible
NOS (iNOS) activity] of calcium. Total low Km cGMP PDE5
activity was assayed in duplicate at 1 mM substrate by the 2 step
method described previously, under linear conditions with and
without added sildenafil citrate (0.1 nM-10 mM) with 0.1 mg/ml
BSA and 0.1 mM EGTA [4]. PKG activity was determined by
colorimetric analysis (CycLex, Nagano, Japan) according to
manufacturer’s instructions [5].
Reactive Oxygen Species (ROS) and Nitrotyrosine
Analysis
Superoxide anion production in penile tissue homogenates was
determined by luminol-enhanced chemiluminescence (EMD
Biosciences). Penile lysate was resuspended in assay buffer to a
final concentration of 100 mM luminal as described [15].
Peroxynitrite was quantitatively assessed by the measurement of
nitrotyrosine by an ELISA assay (Oxis International) [15].
Dihydroethidine (DHE; Molecular Probes), an oxidative fluores-
cent dye, was used to evaluate superoxide anion levels in situ [15].
DHE fluorescence images were obtained with an upright
fluorescence microscope (Nikon). In a separate series of experi-
ments, penile lysate was incubated with a non-selective NOS
inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME; 1 mM),
oxypurinol (1 mM), or apocynin (10 mM) before determination of
ROS production [15].
eNOS Dimer/monomer Ratio by Western Blot
SDS-resistant eNOS dimers and monomers in penile tissue were
assayed using low-temperature SDS-PAGE under nonreducing
conditions. eNOS was immunoprecipitated, and resulting samples
were added to Tris glycine 6% gels (Invitrogen Corp.). Electro-
phoresis was performed in an ice bath at 4uC and gels were stained
(SimplyBlue; Invitrogen Corp.) and destained with water [17].
Statistical Analysis
Data were expressed as mean 6 S.E.M. Differences between
multiple groups were compared by analysis of variance (ANOVA)
followed by a Tukey’s multiple comparisons test. Two-group
analysis was performed by t-test (paired or unpaired as appropri-
ate). Serial studies were tested by repeated measures ANOVA. P
value of less than 0.05 was used as criteria for statistical
significance.
Results
Downregulated NO Signal Transduction Pathway in the
Sickle Cell Mouse Penis
Advancements in the pathophysiology of priapism suggest that
defective neurovascular control of an erection episode accounts for
priapism, as a consequence of PDE5 dysregulation resulting
directly from altered NO/cGMP/PKG signaling in the penis [4],
[5]. In order to confirm our previous observations in eNOS-
deficient mice, we and others have shown that sickle cell mice have
impaired eNOS protein and cGMP synthesis, which manifests as
priapism in vivo and enhanced corporal smooth muscle relaxation
in vitro [6], [7], [9], [10], [18]. Herein, we evaluated the
regulatory biology of the NO/cGMP/PKG/PDE5 pathway in
the sickle cell mouse penis. We found that constitutive (calcium-
dependent) NOS activity was reduced (P,0.05) in penes of
homozygote (Sickle) compared to hemizygous (Hemi) sickle cell
PDE5 Inhibitor Therapy and Priapism
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mice and their wild-type (WT) counterparts (Fig. 1a), while there
was no difference between groups for penile non-constitutive
(calcium-independent) NOS activity (Fig. 2a). We also found that
basal cGMP production, PDE5 activity, and PKG activity were
reduced (P,0.05) in Sickle compared to Hemi and WT mouse
penes (Fig. 1b, c, d). For each of these measurements, the Hemi
mice were similar to WT mice. These findings suggest that the
tonic synthesis of physiologically relevant NO is reduced,
accompanied by a downregulation of its biochemical signaling
cascade in the penis in association with SCD.
Increased Oxidative/Nitrosative Stress in the Sickle Cell
Mouse Penis
Oxidative and nitrosative stress contribute to the cavernosal
tissue damage of priapism in association with reperfusion injury
following episodic relief of ischemia in the penis [19]. We wanted
to determine what redox-active species are present in the penis in
association with SCD. We found that DHE fluorescence,
indicating superoxide production, was uniformly increased in
sections of the penis from Sickle compared to WT mice (Fig. 3a).
DHE localization was increased in all cell types in the Sickle penes,
including endothelial and smooth muscle cells as well as penile
neurons (Fig. 3a). Similarly, luminol activity, indicating reactive
oxygen species (ROS) production, and nitrotyrosine activity,
indicating protein tyrosine nitration by peroxynitrite, were
increased (P,0.05) in the penis of Sickle compared to Hemi and
WT mice (Fig. 3b, c). These results suggest that oxidative stress is
increased in the penis in association with SCD.
Abnormal Erectile Responses of the Sickle Cell Mouse
We have recently demonstrated that sickle cell mice display
spontaneously priapic activity and pronounced erectile responses
to electrical stimulation of the cavernous nerve, as well as
prolonged erections after discontinuation of neurostimulation
[6]. To evaluate whether the priapic phenotype is due to
unrestrained cGMP levels as a result of PDE5 dysfunction, we
conducted erection pharmacostimulation studies in WT, Hemi,
and Sickle mice. Separate in vivo experiments using local
intracavernous injection of NO donor and a PDE5 inhibitor were
conducted. Intracavernous injection of the NO donor DEA/NO
increased erection (ICP) in all 3 groups, but the increase was
markedly more pronounced (P,0.05) in Sickle mice (Fig. 6a). On
the contrary, while intracavernous injection of the PDE5 inhibitor
sildenafil citrate also increased ICP in all 3 groups, this increase
was markedly less pronounced (P,0.05) in Sickle mice (Fig. 6b).
These results suggest that in the Sickle mouse penis the
accumulation of the NO effector cGMP is not degraded due to
the lack of functional PDE5 activity and there is a lack of basal,
inhibitable PDE5 activity in their penes from which to induce
erectile responses, respectively. To further prove this conjecture,
we measured cGMP levels in the penis at baseline and upon
neurostimulation. In contrast to decreased penile cGMP levels at
baseline (Fig. 1b and Fig. 6c), cGMP levels were elevated (P,0.05)
upon cavernous nerve electrical stimulation in Sickle compared to
WT mice (Fig. 6d), indicating unchecked cGMP levels as a basis
for priapism in the Sickle mice penes.
Reversal of Prolonged Erection Tendencies by
Continuous Sildenafil Treatment in the Sickle Cell Mouse
We have made clinical observations that continuous, long-term
PDE5 inhibitor administration to patients with recurrent ischemic
priapism results in alleviation or resolution of priapism recurrences
[12,13]. To explore whether the functional effects of this
intervention are replicated in the animal model, we treated Sickle
mice and their WT counterparts with daily dosing of the PDE5
inhibitor prototype sildenafil for 3 weeks. We found that daily
sildenafil administration to Sickle mice decreased (P,0.05)
frequency of erectile responses pre- and post-cavernous nerve
electrical stimulation (Fig. 7) and decreased (P,0.05) the
detumescence phase of erection (area under the erectile curve
once the stimulation was terminated: 11.162.1 mmHgNsec in
Sickle mice treated with sildenafil vs 9.062.6 mmHgNsec and
19.761.2 mmHgNsec in WT and Sickle mice, respectively. Daily
Figure 1. Downregulation of NO/cGMP/PKG pathway in the
penis of Sickle mice. Baseline calcium-dependent (constitutive) NOS
activity (a), cGMP production (b), PDE5 activity (c), and PKG activity (d)
are reduced in the penis of Sickle compared to WT and Hemi mice. Each
bar represents the mean6 SEM of 5 mice using ANOVA post-hoc Tukey
test. *P,0.05 vs. WT and Hemi.
doi:10.1371/journal.pone.0068028.g001
Figure 2. Calcium-independent NOS activity is not affected by
SCD (a) or continuous sildenafil treatment (b). Each bar
represents the mean 6 SEM of 5 mice using ANOVA post-hoc Tukey
test.
doi:10.1371/journal.pone.0068028.g002
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PDE5 inhibitor therapy had no effect on frequency of erections
pre- and post-neurostimulation in WT mice. These results suggest
that sildenafil administered according to a daily treatment regimen
in the setting of SCD-associated priapism effectively reverts
abnormal erectile mechanisms toward normal penile vascular
homeostasis in the penis.
Normalized NO Signal Transduction Pathway Function in
the Sickle Mouse Penis by Continuous Sildenafil
Treatment
In the current series of experiments, we evaluated the possible
mechanisms whereby daily administered sildenafil influences
priapic activity associated with SCD in this experimental animal
model. We evaluated functional roles of molecular components of
the NO signal transduction pathway in penile tissue of Sickle and
WT mice in response to daily sildenafil treatment. We found that
the basally low penile calcium-dependent NOS activity, cGMP
concentrations, PDE5 activity, and PKG activity were upregulated
(P,0.05) toward normal levels in Sickle mice after continuous
sildenafil treatment (Fig. 8a, b, d, e). Continuous sildenafil
treatment also decreased (P,0.05) abnormally high levels of
cGMP in the penis of Sickle mice upon neurostimulation (Fig. 8c).
There was no change in non-constitutive NOS activity at baseline
in WT and Sickle mice penes after therapy (Fig. 2b). These results
suggest that the molecular basis for restoration of erection
physiology associated with sildenafil treatment in Sickle mice
relates to a normalization of molecular derangements in the NO/
Figure 3. Penes of Sickle mice exhibit increased production of ROS compared to WT and Hemi mice. Superoxide production was
measured by DHE fluorescence (a). Arrows indicate smooth muscle cells; arrowheads indicate endothelial cells; asterisks indicate neurons. ROS
production was measured by luminol-dependant chemiluminescence (b), and protein tyrosine nitration by nitrotyrosine, a marker of peroxynitrite
formation (c). Each bar represents the mean 6 SEM of 6 WT and Sickle mice penes samples and 3 Hemi mice penes samples using ANOVA post-hoc
Tukey test. *P,0.05 vs. WT and Hemi.
doi:10.1371/journal.pone.0068028.g003
Figure 4. ROS production is decreased in the presence of NOS,
NADPH oxidase, and xanthine oxidase inhibitors. All 3 inhibitors
(L-NAME 1 mM, apocynin 10 mM, oxypurinol 1 mM, respectively)
decrease the production of ROS from penes of Sickle mice, indicating
that NOS, NADPH oxidase, and xanthine oxidase are sources of ROS in
penes of Sickle mice. ROS production was measured by luminol activity.
Each bar represents the mean 6 SEM of 6 mice using ANOVA post-hoc
Tukey test. *P,0.05 vs. WT; **P,0.05 vs. Sickle.
doi:10.1371/journal.pone.0068028.g004
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cGMP/PKG/PDE5 signaling pathway in the penis. The stimu-
latory effect (P,0.05) of continuous sildenafil treatment on PKG
activity and cGMP levels in the penis of WT mice upon
neurostimulation (Fig. 8c, e) is conceivably due to overinhibition
of PDE5 in the penis of healthy mice.
Reduced Oxidative/Nitrosative Stress in the Sickle Mouse
Penis with Continuous Sildenafil Treatment
Sildenafil reduces oxidative stress in the peripheral and penile
vasculature with associated improvement in endothelial NO
function [15], [20], [21]. Therefore, we hypothesized that
continuously administered sildenafil may exert benefits by
influencing oxidative/nitrosative stress and endothelial cell biology
in the penis under conditions predisposing priapism. We found a
reduction (P,0.05) in luminol chemiluminescence and nitrotyr-
osine activity in the penis of Sickle mice in response to daily
sildenafil treatment (Fig. 5a, b). We also found that this treatment
increased (P,0.05) the eNOS dimer/monomer ratio in penes of
Sickle mice, suggesting that it prevented eNOS uncoupling (Fig. 5c,
d). These results suggest that daily administered sildenafil
increased eNOS activity by preventing oxidative stress and
particularly eNOS uncoupling in the Sickle mouse penis, which
restored normal erection physiology as it reduced the priapism
phenotype.
Discussion
In the present study, we demonstrate that sildenafil reverses
aberrant signaling of the NO/cGMP/PKG/PDE5 axis that
accounts for abnormal neurovascular control of erectile function
in vivo in an animal model of SCD. The priapic activity that is
observed in the sickle cell mouse is associated with a reduction in
PDE5 regulatory function in the penis due to altered signaling of
endothelial NO and its downstream effectors, cGMP and PKG.
The molecular mechanism underlying the reduction in constitu-
tive NOS activity involves elevated oxidative/nitrosative stress,
principally as a result of functional uncoupling of eNOS. As a
result of PDE5 dysregulation, cGMP generated in abundance in
the erectile tissue during a finite episode of neurostimulation
cannot be degraded and produces unrestrained corporal tissue
relaxation resulting in priapism. This study further establishes that
continuous PDE5 inhibitor therapy restores normal cGMP/PKG/
PDE5 functional levels in erectile tissue allowing proper degrada-
tion of episodically generated cGMP, consistent with controlled
corporal vasorelaxation and erectile function. This action of
sildenafil involves control of oxidative stress principally via
reversion of uncoupled eNOS to functional coupled eNOS in
the penile vasculature, thus restoring endothelial NO biosynthesis
and its downstream signaling.
An important mechanism of decreased endothelial NO
bioavailability is functional uncoupling of eNOS, characterized
by the diversion of electron transfer within the enzyme from L-
arginine oxidation. This molecular event reduces molecular
oxygen to form superoxide instead of NO [22]. Uncoupled
eNOS, thus, contributes to decreased NO bioavailability and
increased ROS formation by the enzyme, conditions which are
both prevalent in SCD-associated vasculopathy [17], [23–25].
Uncoupled NOS appears to provide a dominant source of ROS in
the penis in SCD, because the NOS inhibitor L-NAME reduced
luminol chemiluminescence more than 50% in the sickle cell
mouse penis. Furthermore, the ratio of functional eNOS dimers to
nonfunctional monomers was decreased in the penis of sickle cell
mice, implying eNOS uncoupling with the loss of its dimerization.
The precise mechanism by which eNOS becomes uncoupled is
Figure 5. Reduced ROS production and eNOS uncoupling in the penis of Sickle mice by sildenafil treatment. ROS production was
measured by luminol activity (a; n = 4–6) and nitrotyrosine activity (b; n = 7). Representative Western blots (c) and densitometric analysis (d; n = 5) of
eNOS dimers and monomers in the penis after low-temperature SDS-PAGE. eNOS is uncoupled in the penis of Sickle mice compared to WT mice,
while continuous treatment of Sickle mice with sildenafil citrate recouples eNOS. The results are expressed as dimer/monomer ratio. Each bar
represents the mean 6 SEM using ANOVA post-hoc Tukey test. *P,0.05 vs. WT; **P,0.05 vs. Sickle.
doi:10.1371/journal.pone.0068028.g005
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unclear at this time but may be related to oxidation of the critical
NOS cofactor BH4, depletion of L-arginine, accumulation of
endogenous methylarginines, or S-glutathionylation of eNOS [26].
NADPH oxidase and xanthine oxidase also contribute towards
oxidative stress in the sickle cell mouse penis. However, the
contributions of NADPH oxidase and xanthine oxidase are
apparently smaller compared to that of uncoupled eNOS, because
inhibition of these enzymes reduced luminol activity more
modestly compared to NOS inhibition. Our findings confirm
recent studies, which demonstrated that increased oxidative stress
generated by NADPH oxidase and uncoupled eNOS in the sickle
cell mouse penis contributes to endothelial dysfunction and
cavernosal tissue damage [24], [25]. Further reaction of NO with
superoxide derived from uncoupled eNOS, xanthine oxidase, or
NADPH oxidase produces peroxynitrite, as evidenced by
increased levels of protein tyrosine nitration in the sickle cell
mouse penis. Peroxynitrite is an extremely toxic reactive nitrogen
species, which may further uncouple eNOS. Non-constitutive
iNOS can also contribute to oxidative stress in pathological
conditions by producing excessive NO, which reacts more rapidly
with superoxide to produce peroxynitrite [27]. However, iNOS
does not appear to be an important source of ROS in the sickle
cell mouse penis as calcium-independent NOS activity was low
and not altered in this animal model.
Both increased oxidative stress and eNOS uncoupling decrease
endothelial NO bioavailability in the penis in association with
SCD. Endothelial NO bioavailability in the sickle cell mouse penis
is also reduced by decreased eNOS phosphorylation on its positive
regulatory site Ser-1177 and by decreased eNOS- heat shock
protein (HSP) 90 interaction, as we recently reported [18]. Under
reduced endothelial NO bioactivity at basal, steady state
conditions, cGMP is produced only in low amounts, which is
insufficient to maintain the proper set point for PDE5 function due
to lack of the cGMP-dependent feedback control mechanism [12],
[28]. The notion that PDE5 is downregulated is further supported
by the increased erection physiologic response of sickle cell mice to
intracavernously administered NO donor (because NO effector
cGMP cannot be degraded), and their decreased erectile responses
to intracavernously administered sildenafil (because of the lack of
inhibitable PDE5 activity necessary to increase cGMP). Our
in vivo findings confirm previous in vitro findings of downregu-
lated PDE5 in cavernosal smooth muscle cells of rats [28], mice
[4], and humans [29] under hypoxic conditions, which mimic the
penile ischemia of priapism. These data suggest that the set point
of PDE5 activity in the penis corresponds with endothelial NO
bioavailability in this organ providing new insight into the
regulatory basis for functional penile vascular homeostasis as it
relates to priapism.
Over the past several years PDE5 inhibitors have been explored
for their beneficial therapeutic effects beyond treating male ED. In
the peripheral vasculature [21], [30], [31] as well as in the penis
[15], [32], [33], PDE5 inhibitors exert beneficial effects on eNOS
function and vascular oxidative stress. We now show that
continuous treatment with sildenafil reduced oxidative stress and
prevented eNOS uncoupling in the sickle cell mouse penis. By
recoupling eNOS, sildenafil both decreases ROS production and
increases NO production by the enzyme. While the mechanism
underlying this effect of sildenafil on eNOS is not known, our data
support the hypothesis that it promotes cGMP/PKG-mediated
increases in shear stress and consequent stabilization of eNOS
coupled function. Functional eNOS replenishes endothelial NO
biosynthesis in the penis. This event directly results in improve-
ments in cGMP concentrations and PKG activity in the penile
vascular bed, which normatively resets PDE5 enzyme activity.
Another possible mechanism involves the ability of PDE5
Figure 6. Priapism in Sickle mice is due to unrestrained cGMP/
PDE5 function. Intracavernous pressure (ICP) is increased in response
to intracavernosal (i.c) injection of the NO donor DEA/NO (0.3 mg/kg) (a)
and is decreased in response to i.c. injection of sildenafil citrate
(30 nmol/kg) (b) in Sickle compared to WT and Hemi mice. Basal cGMP
levels are decreased (c), while neurostimulated cGMP levels are
increased (d) in the penis of Sickle compared to WT mice. Each bar
represents the mean 6 SEM of 8 WT and Sickle mice and 6 Hemi mice;
unpaired t-test were used to determine statistical significance. *P,0.05
vs. WT and Hemi.
doi:10.1371/journal.pone.0068028.g006
Figure 7. Normalized penile erection by sildenafil treatment.
Continuous sildenafil citrate treatment (daily for 3 weeks, 100 mg/kg
orally) decreases the frequency of spontaneous erections (erections/hr)
before and after cavernous nerve stimulation (CNS; 2 volts) in Sickle
mice. Each bar represents the mean 6 SEM of 6 WT and WT+sildenafil
and 7 Sickle and Sickle+sildenafil treated mice; ANOVA post-hoc Tukey
test and repeated measures of ANOVA were used to obtain statistical
significance. *P,0.05 vs. WT, **P,0.05 vs. Sickle.
doi:10.1371/journal.pone.0068028.g007
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inhibitors to increase NO biosynthesis and downstream PKG
phosphorylation. Increased PKG activity/phosphorylation in turn
induces positive feedback conformational changes, increasing
cGMP-binding affinity in the regulatory GAF domain of the
PDE5 enzyme and enhancing its cGMP catalytic activity. By
whichever mechanism, we have shown here that continuous use of
a PDE5 inhibitor in a priapism model recovers PDE5 enzymatic
activity in the penis.
In conclusion, this study suggests that focus should be given to
PDE5 as a molecular target for treating recurrent priapism
associated with SCD whereby it directs the use of rational, disease-
specific pharmacotherapy for an ill-defined disorder. Importantly,
our findings suggest that continuous, long-term treatment with
PDE5 inhibitors reverses eNOS uncoupling in the sickle cell
mouse penis which restores endothelial NO synthesis, in support of
the proposal that ‘‘NO imbalance’’ in the penis is a molecular
pathogenic basis for priapism. These observations reveal the
pleiotropic effects of PDE5 inhibitors for erection disorders:
whereas these drugs are commonly used as erectogenic agents for
the treatment of male erectile dysfunction, they also appear useful
as regulators of penile vascular homeostasis, beneficial for
managing priapism associated with SCD.
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